Table 1

Characteristics of CGM-assessed and self-reported hypoglycemia in type 2 diabetes according to treatment

VariableMedian (IQR) for continuous variables, n (%) for proportions
Metformin groupSU groupInsulin group
Number2810051
Female, n (%)18 (64.3)57 (57.0)31 (60.8)
Age, years56.5 (49.5–61.5)55.5 (50.0–62.0)55.0 (49.0–64.0)
Diabetes duration, years5.0 (2.0–8.0)6.0 (3.0–9.0)10.0 (8.0–17.0)
BMI, kg/m226.9 (24.2–29.9)26.7 (23.7–30.1)25.8 (23.1–30.2)
eGFR113.4 (96.8–123.7)112.8 (93.8–121.0)110.8 (92.3–121.8)
Renal impairment, n (%)0 (0)6 (6.0)4 (7.8)
Glycemic control
CGM duration14 (13–14)14 (13–14)14 (13–14)
Average CGM glucose (mmol/L)6.8 (5.4–9.9)8.5 (7.0–12.0)10.1 (8.2–14.5)
HbA1c (%)6.4 (5.8–8.0)8.2 (6.9–9.6)9.8 (8.2–11.3)
HbA1c (mmol/mol)46 (40–64)66 (52–83)84 (67–102)
Fasting glucose7.2 (5.5–10.2)8.2 (6.2–10.7)9.3 (7.0–12.3)
Glucose variability (cv)0.29 (0.26–0.33)0.34 (0.29–0.39)0.39 (0.33–0.47)
SD2.06 (1.65–2.93)3.16 (2.59–3.85)4.0 (3.3–5.2)
Percent time spent in optimal range78.1 (55.3–86.4)60.1 (33.8–73.9)40.1 (22.2,–55.4)
Percent time above 1010.9 (1.3–35.3)31.9 (14.3–66.0)49.3 (30.8–74.2)
CGM hypoglycemia per week
Episodes <3 mmol/L1 (0–2.3)0.5 (0–3.0)2 (0–6.0)
Total time/week <3 mmol/L, min39.2 (0–174.8)17.0 (0–229.3)127.5 (0–637.5)
Per cent time <3 mmol/L (%)0.39 (0, 1.74)0.17 (0, 2.26)1.27 (0, 6.42)
Self-reported hypoglycemia, n (%)
History of hypoglycemia events, n (%)7 (25.0)28 (28.0)23 (45.1)
Hospitalized for hypoglycemia in the previous 12 months, yes1 (3.6)3 (3.0)6 (11.8)
Hospitalized for hypoglycemia in the previous 12 months, % (95% CI)3.6 (0.1 to 18.3)3.0 (0.6 to 8.5)11.8 (4.4 to 23.9)
  • BMI, body mass index; CGM, continuous glucose monitoring; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; SU, sulphonylurea.